### Opioid Prescriptions

Opioid prescriptions constitute more than half of the total prescription pain market. Pfizer leads the industry for opioid R&D.

### Source

1. Pressures and Opportunities in Pain (Pharma Intelligence, 2016)
2. Based on available data from CDC Wonder (Drug Abuse, 2017)
3. In February 2016, the FDA revised and outlined its strategy to combat the growing epidemic of opioid abuse, dependence, and overdose in the US (FDA, 2016a)
4. FDA requests removal of Opana ER for risks related to abuse (FDA, 2017)
5. Statement from FDA Commissioner Scott Gottlieb, M.D. – FDA is taking new steps to help assess opioid drugs with abuse-deterrent properties (FDA, 2017)

### Timeline of Key Drug Approvals During the Opioid Drug Crisis

- **Dec 1995**: Oxycontin becomes the first long-acting opioid therapy widely marketed with a lower potential for abuse only to see the initial formulation eventually withdrawn from the market.
- **Aug 2009**: The FDA comes down on Opana ER after widespread abuse and requests company pull its drug from the market.
- **Feb 2016**: The anticipated annual market size for opioid drugs becomes $18.4B by 2020.
- **June 2017**: The FDA announces a two-day public meeting scheduled for July 2017 to determine if ADP opioids are having their intended impact by limiting abuse to curb the epidemic.
- **Apr 2010**: Oxycontin receives approval of an abuse-deterrent formulation, which replaced the older tablets (specific label claim not awarded until 2013).
- **Jun/Jul 2017**: Informa Pharma Intelligence’s Biomedtracker and SERMO surveyed 30 US primary care physicians treating patients with chronic pains that prescribe opioids to better understand first-hand how these controversial drugs are perceived. Findings suggest:
  - Half of the physicians surveyed think abuse-deterrent opioids will play no or only a slightly impactful role in combating the opioid epidemic in the US.
  - The majority of physicians surveyed don’t know if legislation has been adopted in their state requiring that abuse-deterrent opioids be covered by insurers.
  - Half of the physicians prescribe opioids to just 0–20% of their patients to treat chronic pain.

### Opioid Related Deaths in the US

The anticipated annual market size for opioid drugs in the US by 2020.

### Professional Perspectives

Informa Pharma Intelligence’s Biomedtracker and SERMO surveyed 30 US primary care physicians treating patients with chronic pains that prescribe opioids to better understand first-hand how these controversial drugs are perceived. Findings suggest:

- Half of the physicians surveyed think abuse-deterrent opioids will play no or only a slightly impactful role in combating the opioid epidemic in the US.
- The majority of physicians surveyed don’t know if legislation has been adopted in their state requiring that abuse-deterrent opioids be covered by insurers.
- Half of the physicians prescribe opioids to just 0–20% of their patients to treat chronic pain.